.jpeg)
2026-07-31 05:29:27
Tivozanib (brand name FOTIVDA) is an oral, highly selective VEGFR tyrosine kinase inhibitor primarily indicated for patients with advanced renal cell carcinoma who have progressed after multiple prior systemic therapies, representing a key advancement in precision-targeted kidney cancer treatment.
2026-07-30 06:32:34
A systematic review of the highly selective MET inhibitor capmatinib in MET exon 14 skipping mutation non-small cell lung cancer, covering efficacy data, horizontal comparison with tepotinib, first-line and later-line monotherapy strategies, and emerging combination therapy directions.
2026-07-30 04:19:01
A comprehensive analysis of the highly selective RET inhibitor pralsetinib, covering discontinuation criteria, comparative efficacy with selpercatinib, and first-line and later-line treatment strategies for RET fusion-positive solid tumors.
2026-07-30 03:05:05
A comprehensive overview of dabrafenib's approved indications, monotherapy versus combination with trametinib, and comparative analysis with vemurafenib and encorafenib for BRAF V600-mutant solid tumors.
2026-07-23 05:37:53
Cabozantinib (Cabozantinib) capsules are a multi-target tyrosine kinase inhibitor approved for progressive, metastatic medullary thyroid cancer (MTC), inhibiting RET, MET, and VEGFR signaling pathways to control tumor progression.
2026-07-23 02:50:52
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor for ALK-positive advanced NSCLC with potent ALK inhibition and superior CNS penetration. This article covers its mechanism of action, therapeutic advantages, efficacy factors, and adverse effect management.
2026-07-23 02:29:04
Pemigatinib is an FGFR inhibitor for FGFR2 fusion/rearrangement-positive cholangiocarcinoma. This article covers common adverse effects (hyperphosphatemia, alopecia, stomatitis), ophthalmologic monitoring requirements, and dose modification strategies for safe long-term treatment.
2026-07-23 02:21:07
Selpercatinib is a selective RET kinase inhibitor for RET fusion-positive NSCLC and RET-mutant medullary thyroid carcinoma. This guide addresses meal timing, twice-daily dosing, missed dose management, and key monitoring considerations during treatment.
2026-07-23 02:11:21
Mitotane is the cornerstone drug for adrenocortical carcinoma (ACC) treatment. This article covers initial dosing, target plasma concentration range (14–20 mg/L), monitoring frequency, and adverse effect management for safe and effective therapy.
2026-07-21 07:22:56
A balanced review of leflunomide-related eye symptoms, incidence, monitoring recommendations, and management strategies for rheumatoid arthritis patients.
2026-07-21 07:17:20
A structured overview of progression criteria, molecular profiling, and sequential treatment strategies following resistance to garsorasib in advanced NSCLC.
2026-07-20 07:28:12
Capivasertib is an oral AKT inhibitor with molecular formula C₂₁H₂₅ClN₆O₂, selectively binding to AKT protein to block PI3K/AKT signaling, used in precision therapy for breast cancer and other tumors.
